The new rule, called Order 818, lets China's roughly 1,700 top tier hospitals develop and offer cell, gene, and gene editing therapies to patients without going through the National Medical Products Administration (NMPA), China's central drug regulator, and charge for them.
China's top-tier hospitals can now clinically translate and charge patients for cell, gene, and gene-editing therapies without going through the country's central drug regulator, an institutional change that adds a second runway to the global map of advanced-medicine development and asks a fresh question: what compresses the bench-to-bed distance for these treatments, central approval or distributed hospital capacity?
The rule, a State Council regulation formally called Order 818, covers clinical research, clinical translation, and clinical application of "biomedical new technologies" whose mechanism sits at the cellular or molecular level. In plain terms, it carves out a defined class of Chinese hospitals, the 3A tier, roughly the 1,700 highest-classified facilities in the country's hospital grading system, concentrated in major cities, and lets them run translational programs and bill patients for the resulting therapies without first registering those therapies with the National Medical Products Administration, or NMPA, the central regulator that ordinarily approves new drugs and biologics.
That distinction matters. Therapies that go the Order 818 route are not approved drugs. They are hospital-delivered clinical translations of biomedical new technologies, charged at the point of care under a separate institutional logic. Cell, gene, and gene-editing therapies are the named categories, and the global advanced-therapy map, long organized around a single assumption, that bench science reaches the bedside through a central regulator's approval, is now visibly plural. China's bet is that hospital-class translational capacity plus point-of-care reimbursement will compress the bench-to-bed distance in a way that central approval has not.
Place Order 818 against one familiar comparator and the architecture becomes legible. Under the European Union's ATMP regulation, the hospital exemption (Article 3 of Regulation EC No 1394/2007) permits individual member states to authorize advanced therapy use on a named-patient basis within a single hospital, without requiring centralized EMA marketing authorization. The United States, under the 21st Century Cures Act, has established expanded-access and RIGHT-to-try pathways that allow individual patients to receive investigational therapies outside clinical trials. Both are narrow carve-outs for individual patients under carefully controlled conditions. Order 818 is broader in design: it institutionalizes a hospital-led translational pathway with charging rights attached, across a distributed network of 1,700 tertiary facilities, for an entire category of advanced therapies, without requiring central drug registration. The Chinese model is closer to a standing parallel development track than to an exception.
The framework leaves three open questions that matter to anyone watching the field.
First, the boundary. The regulation itself does not yet specify which therapies fall under Order 818 and which remain the NMPA's exclusive domain. The line between a biomedical new technology subject to hospital translation and a drug or biologic subject to central registration will be drawn by boundary delineation guidelines that have not been issued. Until those guidelines land, developers and investors do not have a clean rule for which pathway any given program is supposed to take, and that uncertainty is not theoretical, since the choice of pathway will shape the cost, timeline, and evidence base a therapy must clear before reaching patients.
Second, safety and equity when hospitals charge before central registration. Allowing top-tier hospitals to bill patients for therapies that have not gone through the NMPA's evidence and review process raises the question of who monitors outcomes, who pays when a translation goes wrong, and who carries the long-tail safety data once a therapy is in clinical use. A central registry, a defined adverse-event reporting chain, and a clear channel for moving a hospital-translated therapy into a registration track when evidence supports it are not yet visible in the rule itself.
Third, geography. 3A hospitals are concentrated in Beijing, Shanghai, Guangzhou, and a handful of other major cities. A "second track" that runs only through the highest-tier facilities is, in practice, a second track for patients who live near one of them, and the access benefit will be uneven across regions and income levels until lower-tier hospitals are brought into the framework or parallel capacity is built elsewhere.
The constructive read is that China has added an institutional route, and the global advanced-therapy community now has a testable hypothesis in front of it: whether a hospital-led translational pathway with point-of-care reimbursement can move advanced therapies to patients faster than a central-approval funnel, and at what cost in safety monitoring and equity. The caveats are not footnotes; they are the conditions under which the experiment will be read.
What to watch next is concrete. The boundary delineation guidelines. The first reported adverse events and outcomes from hospital-translated programs. The first moves by NMPA to clarify handoff between the two tracks. The first major therapy that chooses the Order 818 route over a traditional registration filing. Each of those will tell the field whether the second runway is a parallel path or a different destination.